Trending...
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
BOSTON, May 20, 2024 ~ Chroma Medicine, Inc. has recently announced the appointment of Jenny Marlowe, Ph.D., as their new Chief Development Officer. Dr. Marlowe brings with her a wealth of experience and expertise in the field of genomic medicine, making her a valuable addition to the company's leadership team.
According to Catherine Stehman-Breen, M.D., CEO of Chroma, the company is thrilled to have Dr. Marlowe on board during this crucial time as they prepare to transition to clinical trials. Her leadership and knowledge will be instrumental in bringing their innovative epigenetic editing therapies to patients.
Prior to joining Chroma, Dr. Marlowe served as the Chief Scientific Officer at Solid Biosciences (previously AvantiBio), where she led discovery, research, and translational development. She also held the position of Vice President of Preclinical and Translational Development at bluebird bio, where she played a key role in the development of Zynteglo, a gene therapy for beta thalassemia that has since been approved.
More on Ohio Pen
Dr. Marlowe's career began at Novartis, where she held various leadership positions including Global Head of Strategic Planning and Communication and Director of Translational Safety Models in Preclinical Safety. She holds a Ph.D. in Molecular Toxicology from the University of Cincinnati and a B.S. in Zoology from Miami University.
In her new role at Chroma, Dr. Marlowe will be focusing on advancing their epigenetic editing platform which utilizes the cell's natural system to regulate gene expression without altering DNA. This technology has shown great potential for creating groundbreaking medicines.
Expressing her excitement about joining Chroma, Dr. Marlowe stated that their epigenetic editing platform is an incredibly compelling technology for developing transformative medicines. She is eager to work with the team at Chroma and help bring this new class of genomic therapies to patients.
With Dr. Marlowe's extensive experience and expertise, Chroma is well-positioned to continue their pioneering work in the field of genomic medicine and bring hope to patients in need of innovative treatments.
According to Catherine Stehman-Breen, M.D., CEO of Chroma, the company is thrilled to have Dr. Marlowe on board during this crucial time as they prepare to transition to clinical trials. Her leadership and knowledge will be instrumental in bringing their innovative epigenetic editing therapies to patients.
Prior to joining Chroma, Dr. Marlowe served as the Chief Scientific Officer at Solid Biosciences (previously AvantiBio), where she led discovery, research, and translational development. She also held the position of Vice President of Preclinical and Translational Development at bluebird bio, where she played a key role in the development of Zynteglo, a gene therapy for beta thalassemia that has since been approved.
More on Ohio Pen
- Lore Link is Here to Help Organize Your Game
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- 216 Marketing Launches New Website to Help Local Businesses Dominate Online in Northeast Ohio
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- Powerful Stories and Shared Sisterhood Shine at "An Evening with the Author" Featuring Staci Kirk
Dr. Marlowe's career began at Novartis, where she held various leadership positions including Global Head of Strategic Planning and Communication and Director of Translational Safety Models in Preclinical Safety. She holds a Ph.D. in Molecular Toxicology from the University of Cincinnati and a B.S. in Zoology from Miami University.
In her new role at Chroma, Dr. Marlowe will be focusing on advancing their epigenetic editing platform which utilizes the cell's natural system to regulate gene expression without altering DNA. This technology has shown great potential for creating groundbreaking medicines.
Expressing her excitement about joining Chroma, Dr. Marlowe stated that their epigenetic editing platform is an incredibly compelling technology for developing transformative medicines. She is eager to work with the team at Chroma and help bring this new class of genomic therapies to patients.
With Dr. Marlowe's extensive experience and expertise, Chroma is well-positioned to continue their pioneering work in the field of genomic medicine and bring hope to patients in need of innovative treatments.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- "Drink Like It's 1776… Just Kidding, It's 1932." A Golden Age Patriotic Pop-Up
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Nationwide Completes Acquisition of Allstate Employer Stop Loss Business for $1.25 billion
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
- $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
- Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock